Disease Severity, Mortality Risk, and Muscle Function in Intensive Care Unit Patients
ConditionCritically Ill Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIstinye University
About this trial
Intensive Care Units are specialized, technologically advanced hospital units that provide continuous monitoring and care from multiple healthcare disciplines for patients who are critically ill and face a high risk of death or serious health problems. Prolonged periods of immobility, which are common during treatment in these units, can cause serious complications such as muscle weakness, decline in physical function, and a lower quality of life. There are scoring systems designed to predict the severity of a patient's illness and their likely outcomes, such as the scoring system called the Acute Physiology and Chronic Health Evaluation version two. However, these scoring systems are not yet widely used as a regular part of patient care. Although weakness and wasting of muscles away from the center of the body are known to affect the recovery process of patients who survive intensive care treatment, the connection between how severe the illness is and the strength of the muscles used for breathing, the structure of peripheral muscles, and their biomechanical characteristics is still not fully understood. This study aims to explore these relationships to help improve physiotherapy and rehabilitation treatments for patients in intensive care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients admitted to the intensive care unit who are not dependent on mechanical ventilation and meet the inclusion and exclusion criteria will be included in the study.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
45 Participants
are grouped into 1 trial groupGroup A: Critical care patient
Trial outcomes
Primary outcomes
1
Course of Disease in Intensive Care Patients, Mortality risk:
The patient's mortality rate will be assessed using the Acute Physiology and Chronic Health Evaluation II score. The Acute Physiology and Chronic Health Evaluation II score is commonly used for patients treated in the intensive care unit. It is based on an initial score comprising 12 components and is evaluated on a scale from 0 to 71 points. The assessment consists of three sections: physiological scores ranging from 0-60 points, age scores ranging from 0-6 points, and comorbidity scores ranging from 0-5 points. A higher total Acute Physiology and Chronic Health Evaluation II score indicates greater severity of the patient's condition (15).
Time frame
4 weeks2
Assessment of Peripheral Muscle Architecture:
Quadriceps femoris muscle thickness will be measured as the distance between the upper border of the femur and the lower border of the subcutaneous tissue. Measurements will be taken 15 cm proximal to the superior border of the patella using a tape measure (19). After each patient, the ultrasound probe will be disinfected by wiping with 70% isopropyl alcohol.
Time frame
4 weeksSecondary outcomes
1
Muscle Tone:
Peripheral muscle stiffness will be assessed using the MyotonPRO device (Myoton AS, Estonia). Tone refers to the tension of the tissue at rest. There is a direct relationship between the measured value and tissue tension.
Time frame
4 weeks2
Measurement of Respiratory Muscle Strength:
Respiratory muscle strength will be assessed using a portable electronic device (Micro Medical Micro RPM, Rochester, UK) to measure maximal inspiratory mouth pressure and maximal expiratory mouth pressure in cmH₂O. Maximal inspiratory mouth pressure is recorded during maximal inspiration against an occluded airway after full expiration, sustained for 1-3 seconds; maximal expiratory mouth pressure is recorded during maximal expiration after full inspiration. The best of three trials will be expressed as a percentage of age- and sex-adjusted reference values. To prevent infection, disposable mouthpieces and filters will be used, with device surfaces disinfected using alcohol-based solutions, and mouthpieces sterilized with ethyl alcohol and specialized equipment.
Time frame
4 weeks3
Elasticity:
It will be measured by using the MyotonPRO device (Myoton AS, Estonia). Elasticity is the ability of the tissue to return to its original shape after the removal of deforming forces. Tissue elasticity and the measured value are inversely related; as the logarithmic decrement decreases, the tissue's ability to return to its original shape increases.
Time frame
4 weeks4
Dynamic Stiffness
Peripheral muscle stiffness will be assessed using the MyotonPRO device (Myoton AS, Estonia). Dynamic stiffness (measured in Newtons per meter, N/m) is defined as the resistance of soft tissues to destructive external forces. Tissue stiffness and the measured value are inversely related.
Time frame
4 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov